Michael Zand – Page 800

Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta … – GlobeNewswire (press release)

2017-12-12 Michael Zand NEWS

Is there really a covert manipulation of UN discussions about regulating gene drives? – Science Magazine

Science MagazineIs there really a covert manipulation of UN discussions about regulating gene drives?Science MagazineThe emails disclose that Emerging Ag is working with Kuiken and other AHTEG members to help recruit scientists to an open online forum … Continue reading

2017-12-11 Michael Zand NEWS

City of Hope Physicians Report on New CAR-T Cell Therapy for Acute Myeloid Leukemia, Blastic Plasmacytoid … – Business Wire (press release)

City of Hope Physicians Report on New CAR-T Cell Therapy for Acute Myeloid Leukemia, Blastic Plasmacytoid …Business Wire (press release)“This is a very promising CAR-T cell therapy for AML and BPDCN patients and furthermore, the side effects they exp… Continue reading

2017-12-11 Michael Zand NEWS

Crispr Therapeutics Plans Its First Clinical Trial for Genetic Disease – WIRED

Nasdaq

Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta …
GlobeNewswire (press release)
CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from experiments to demonstrate expanded CRISPR genome editing strategies in hematopoietic stem cells for …
Editas Medicine Out with News, Shares DropBaystreet.ca
Zacks’ 7 Best Strong Buys for 2018Zacks.com

all 52 news articles »

2017-12-11 Michael Zand NEWS

Mustang Bio’s MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and … – Nasdaq

WIRED

Crispr Therapeutics Plans Its First Clinical Trial for Genetic Disease
WIRED
In late 2012, French microbiologist Emmanuelle Charpentier approached a handful of American scientists about starting a company, a Crispr company. They included UC Berkeley’s Jennifer Doudna, George Church at Harvard University, and his former postdoc …
CRISPR: Five Ways to Maximize Its PotentialR & D Magazine

all 2 news articles »

2017-12-11 Michael Zand NEWS

Mustang Bio’s MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and … – Nasdaq

Mustang Bio’s MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and …
Nasdaq
NEW YORK, Dec. 11, 2017 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (“CAR …
Fortress Biotech Announces Positive Clinical Data From Fortress …GlobeNewswire (press release)

all 2 news articles »

2017-12-11 Michael Zand NEWS

Mustang Bio’s MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and … – GlobeNewswire (press release)

all 2 news articles »

2017-12-11 Michael Zand NEWS

New CAR-T Cancer Studies Aim to Treat Those With No Other Options – Futurism

Mustang Bio’s MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and …
GlobeNewswire (press release)
NEW YORK, Dec. 11, 2017 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (“CAR …
Fortress Biotech Announces Positive Clinical Data From Fortress Companies Presented at the 59th American Society …Nasdaq

all 2 news articles »

2017-12-11 Michael Zand NEWS

1
…
798
799
800
801
802
…
3,823

Futurism

New CAR-T Cancer Studies Aim to Treat Those With No Other Options
Futurism
Two studies have been published detailing the results of clinical trials involving CAR-T treatment, where a patient’s own T-cells are used to fight cancer.
CAR T Progress: Global Submissions for Kymriah, 42% Ongoing Response With Yescarta in ZUMA-1 PatientsAJMC.com Managed Markets Network
India: US FDA Approves Yescarta™ (Axicabtagene Ciloleucel): Becomes First CAR T Therapy Approved For The …Mondaq News Alerts
ASH: Long-term CAR-T data look good for Gilead—but good …FiercePharma
StreetInsider.com –Pharmacy Today, American Pharmacists Association, pharmacist.com
all 13 news articles »

Login

Cart

All posts by: Michael Zand

Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta … – GlobeNewswire (press release)

Is there really a covert manipulation of UN discussions about regulating gene drives? – Science Magazine

City of Hope Physicians Report on New CAR-T Cell Therapy for Acute Myeloid Leukemia, Blastic Plasmacytoid … – Business Wire (press release)

Crispr Therapeutics Plans Its First Clinical Trial for Genetic Disease – WIRED

Mustang Bio’s MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and … – Nasdaq

Mustang Bio’s MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and … – Nasdaq

Mustang Bio’s MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and … – GlobeNewswire (press release)

New CAR-T Cancer Studies Aim to Treat Those With No Other Options – Futurism